SEC Form 4 · accession 0001209191-17-045915
AKCEA THERAPEUTICS, INC. · AKCA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
IONIS PHARMACEUTICALS INC
10% Owner
Period of report
Jul 19, 2017
Accepted (ET)
Jul 21, 2017 · 4:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001662524
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 19, 2017 | C | 28,884,540 | — | A | 28,884,540 | D | |
| Common StockF2 | Jul 19, 2017 | J | 13,438,339 | — | A | 42,322,879 | D | |
| Common Stock | Jul 19, 2017 | P | 3,125,000 | $8.00 | A | 45,447,879 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Preferred StockF1 | — | Jul 19, 2017 | C | 28,884,540 | D | — | — | Common Stock | 28,884,540 | 0 | D |
Explanation of responses
- F1Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a one-for-one basis. The shares have no expiration date.
- F2Shares issued in satisfaction of the Issuer's obligations to the Reporting Person pursuant to a line of credit.
- F3The shares were purchased at the Issuer's initial public offering.